drugset / Trial / NCT02953275
Synergistic Effect of Vedolizumab and Pentoxifylline
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the synergistic effect and clinical benefits of vedolizumab and pentoxifylline in the management of patients with inflammatory bowel disease.
Timeline
- Start
- 2017-04-13
- Primary completion
- 2019-03-18
- Completion
- 2019-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentoxifylline | Small molecule | 400 mg | Oral |
| Background | Vedolizumab | Monoclonal antibody | 300 mg | Intravenous |